Literature DB >> 20574671

Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.

Jung Ah Lee1, Kwan-Il Kim, Jeoung Won Bae, Young-Hoon Jung, Hyonggin An, Eun Sook Lee.   

Abstract

We analyzed breast cancer subtypes using Korean Breast Cancer Society Registration Program data to compare clinical features and prognosis for triple-negative breast cancer (TNBC). A cohort of 26,767 breast cancer patients were divided in four groups: luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+ HER2+), HER2+ (ER-, PR-, HER2+), and triple-negative (ER-, PR-, HER2-). Clinicopathologic factors were evaluated. The luminal A (14,437 patients, 53.9%) subtype was the largest in our study. Compared with luminal A subtype, TNBC correlated with younger age, more aggressive characteristics and poor overall survival and breast cancer-specific survival. The hazard rate showed a peak at 24 months for the TNBC subtype, but after 60 months, risk was similar to that of the luminal A subtype. Higher T, N stage and histologic grade, and lymphatic and vascular invasion showed poor prognosis in TNBC patients, but on multivariate analysis only histologic grade and ki-67 status were related. Young age was related to poor prognosis in the luminal A subtype, however, age was not related to prognosis in the TNBC subtype. Of the 5,586 TNBC patients, 282 patients (7.11%) expired within 3 years of diagnosis. T and N stage and grade were significantly associated with prognosis on multivariate analysis. TNBC subtype is characterized by younger age with poorer outcome. However, younger age is not related to prognosis, and mortality risk decreases to that of the luminal A subtype, which is known to have the best prognosis after a few years.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20574671     DOI: 10.1007/s10549-010-0998-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  26 in total

1.  Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.

Authors:  Martin H Pedersen; Brian L Hood; Hans Christian Beck; Thomas P Conrads; Henrik J Ditzel; Rikke Leth-Larsen
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

2.  Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival.

Authors:  Geok-Hoon Lim; Puay-Hoon Tan; Ana Richelia Jara-Lazaro; Aye Aye Thike; Wey-Cheng Sim; Von-Bing Yap; George Wai-Cheong Yip
Journal:  Singapore Med J       Date:  2014-09       Impact factor: 1.858

3.  A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis.

Authors:  C Hamm; M El-Masri; G Poliquin; V Poliquin; J Mathews; S Kanjeekal; Y Alam; S Kulkarni; T Elfiki
Journal:  Curr Oncol       Date:  2011-08       Impact factor: 3.677

4.  A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.

Authors:  Tae-Kyung Yoo; Jun Kang; Awon Lee; Byung Joo Chae
Journal:  Breast Cancer Res Treat       Date:  2022-01-12       Impact factor: 4.872

5.  Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound.

Authors:  Eun Bi Ryu; Jung Min Chang; Mirinae Seo; Sun Ah Kim; Ji He Lim; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2014-06-04       Impact factor: 5.315

6.  Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.

Authors:  Gilda Schmidt; Christoph Gerlinger; Ingolf Juhasz-Böss; Elmar Stickeler; Achim Rody; Cornelia Liedtke; Pauline Wimberger; Theresa Link; Eberhard Müller; Tanja Fehm; Manuela Abel; Stefan Stein; Rainer Bohle; Jan Endrikat; Erich-Franz Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-23       Impact factor: 4.553

7.  Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients.

Authors:  Rosalind P Candelaria; Beatriz E Adrada; Kenneth Hess; Lumarie Santiago; Deanna L Lane; Alastair M Thompson; Stacy L Moulder; Monica L Huang; Elsa M Arribas; Gaiane M Rauch; Jessica W T Leung; W Fraser Symmans; Vicente Valero; Elizabeth E Ravenberg; Jason B White; Wei Tse Yang
Journal:  Eur J Radiol       Date:  2020-07-10       Impact factor: 3.528

8.  Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?

Authors:  Gaurav Agarwal; Gitika Nanda; Punita Lal; Anjali Mishra; Amit Agarwal; Vinita Agrawal; Narendra Krishnani
Journal:  World J Surg       Date:  2016-06       Impact factor: 3.352

9.  Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients.

Authors:  Katarzyna Pogoda; Anna Niwińska; Magdalena Murawska; Tadeusz Pieńkowski
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

10.  Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study.

Authors:  Byung Ho Son; Sei Hyun Ahn; Sung-Won Kim; Eunyoung Kang; Sue K Park; Min Hyuk Lee; Woo-Chul Noh; Lee Su Kim; Yongsik Jung; Ku Sang Kim; Dong-Young Noh; Byung-In Moon; Young Jin Suh; Jeong Eon Lee; Doo Ho Choi; Sung Yong Kim; Sung Hoo Jung; Cha Kyong Yom; Hyde Lee; Jung-Hyun Yang
Journal:  Breast Cancer Res Treat       Date:  2012-03-02       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.